Jump to content
Your browser is out of date. It has known security flaws and may not display all features of this websites. Learn how to update your browser[Close]


Novartis Korea staff indicted for corruption

Basel-based pharmaceutical company Novartis has confirmed news reports that six senior employees of their subsidiary in South Korea have been indicted by the Seoul Western District Prosecutor’s Office for corruption.

The employees are believed to have offered illegal rebates and kickbacks to doctors amounting to 2.6 billion won (CHF 2.3 million) between 2011 and 2016.

Altogether, 34 people – including 15 doctors and five heads of medical journals – have been included in the investigation, which began in February when authorities raided the Novartis Korea offices in Seoul on suspicion of bribing doctors to promote product sales.

The six staff members are also accused of paying for doctors to travel to international conferences, and of holding meetings with doctors that were, Novartis said in a Thursday statement quoted on Reuters, “inconsistent with our culture and the expectations society has for us”.

South Korean laws ban drug companies from providing doctors rebates or discounts for the drugs they prescribe. According to the prosecution, Novartis' South Korean associates, including former Novartis Korea chief executive Moon Hak-sun, tried to go around the laws by funding academic events organized by publishers of medical journals, where the invited doctors allegedly received kickbacks disguised as attendance fees.

Under the nation’s law, drug companies that give rebates or discounts to physicians who prescribe their products can have the sale of those products banned for up to six months; however it has not been confirmed that this will be the case for Novartis.

The Swiss company has also launched an internal investigation aimed at identifying and disciplining any wrongdoers. "Novartis does not tolerate misconduct and we are already implementing a remediation plan in Korea based on the findings from our own investigation," the company said.

Sign up for our free newsletter and get the top stories delivered to your inbox.

swissinfo.ch and agencies


All rights reserved. The content of the website by swissinfo.ch is copyrighted. It is intended for private use only. Any other use of the website content beyond the use stipulated above, particularly the distribution, modification, transmission, storage and copying requires prior written consent of swissinfo.ch. Should you be interested in any such use of the website content, please contact us via contact@swissinfo.ch.

As regards the use for private purposes, it is only permitted to use a hyperlink to specific content, and to place it on your own website or a website of third parties. The swissinfo.ch website content may only be embedded in an ad-free environment without any modifications. Specifically applying to all software, folders, data and their content provided for download by the swissinfo.ch website, a basic, non-exclusive and non-transferable license is granted that is restricted to the one-time downloading and saving of said data on private devices. All other rights remain the property of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited.